KR20190003711A - 중수소화된 jak 저해제를 이용한 탈모 장애의 치료 - Google Patents

중수소화된 jak 저해제를 이용한 탈모 장애의 치료 Download PDF

Info

Publication number
KR20190003711A
KR20190003711A KR1020187034867A KR20187034867A KR20190003711A KR 20190003711 A KR20190003711 A KR 20190003711A KR 1020187034867 A KR1020187034867 A KR 1020187034867A KR 20187034867 A KR20187034867 A KR 20187034867A KR 20190003711 A KR20190003711 A KR 20190003711A
Authority
KR
South Korea
Prior art keywords
compound
day
pharmaceutically acceptable
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187034867A
Other languages
English (en)
Korean (ko)
Inventor
아만다 티. 와그너
제임스 브이. 카셀라
필립 비. 그레이엄
버지니아 브라만
비니타 유탐싱
제나 본 헤흔
콜린 이. 해밀턴
Original Assignee
콘서트 파마슈티컬즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60203616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20190003711(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 콘서트 파마슈티컬즈, 인크. filed Critical 콘서트 파마슈티컬즈, 인크.
Priority to KR1020237019001A priority Critical patent/KR102810262B1/ko
Publication of KR20190003711A publication Critical patent/KR20190003711A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020187034867A 2016-05-04 2017-05-04 중수소화된 jak 저해제를 이용한 탈모 장애의 치료 Ceased KR20190003711A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237019001A KR102810262B1 (ko) 2016-05-04 2017-05-04 중수소화된 jak 저해제를 이용한 탈모 장애의 치료

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201662331827P 2016-05-04 2016-05-04
US62/331,827 2016-05-04
US201662338869P 2016-05-19 2016-05-19
US62/338,869 2016-05-19
US201662418774P 2016-11-07 2016-11-07
US62/418,774 2016-11-07
US201662419237P 2016-11-08 2016-11-08
US62/419,237 2016-11-08
US201662434404P 2016-12-14 2016-12-14
US62/434,404 2016-12-14
US201762466358P 2017-03-02 2017-03-02
US62/466,358 2017-03-02
US201762492758P 2017-05-01 2017-05-01
US62/492,758 2017-05-01
PCT/US2017/031142 WO2017192905A1 (en) 2016-05-04 2017-05-04 Treatment of hair loss disorders with deuterated jak inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237019001A Division KR102810262B1 (ko) 2016-05-04 2017-05-04 중수소화된 jak 저해제를 이용한 탈모 장애의 치료

Publications (1)

Publication Number Publication Date
KR20190003711A true KR20190003711A (ko) 2019-01-09

Family

ID=60203616

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020187034867A Ceased KR20190003711A (ko) 2016-05-04 2017-05-04 중수소화된 jak 저해제를 이용한 탈모 장애의 치료
KR1020257015799A Pending KR20250070139A (ko) 2016-05-04 2017-05-04 중수소화된 jak 저해제를 이용한 탈모 장애의 치료
KR1020237019001A Active KR102810262B1 (ko) 2016-05-04 2017-05-04 중수소화된 jak 저해제를 이용한 탈모 장애의 치료

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020257015799A Pending KR20250070139A (ko) 2016-05-04 2017-05-04 중수소화된 jak 저해제를 이용한 탈모 장애의 치료
KR1020237019001A Active KR102810262B1 (ko) 2016-05-04 2017-05-04 중수소화된 jak 저해제를 이용한 탈모 장애의 치료

Country Status (21)

Country Link
US (3) US10561659B2 (cg-RX-API-DMAC7.html)
EP (2) EP4424367A3 (cg-RX-API-DMAC7.html)
JP (3) JP7145080B2 (cg-RX-API-DMAC7.html)
KR (3) KR20190003711A (cg-RX-API-DMAC7.html)
CN (3) CN122440641A (cg-RX-API-DMAC7.html)
AU (3) AU2017261286B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018072339A2 (cg-RX-API-DMAC7.html)
CA (1) CA3022519A1 (cg-RX-API-DMAC7.html)
DK (1) DK3452039T3 (cg-RX-API-DMAC7.html)
ES (1) ES2988629T3 (cg-RX-API-DMAC7.html)
FI (1) FI3452039T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241345T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068643T2 (cg-RX-API-DMAC7.html)
LT (1) LT3452039T (cg-RX-API-DMAC7.html)
MX (6) MX388054B (cg-RX-API-DMAC7.html)
PL (1) PL3452039T3 (cg-RX-API-DMAC7.html)
PT (1) PT3452039T (cg-RX-API-DMAC7.html)
RS (1) RS66006B1 (cg-RX-API-DMAC7.html)
SI (1) SI3452039T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400389T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017192905A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10561659B2 (en) * 2016-05-04 2020-02-18 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors
EP3921318A1 (en) * 2019-02-06 2021-12-15 Concert Pharmaceuticals Inc. Process for preparing enantiomerically enriched jak inhibitors
WO2021236139A1 (en) * 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
US12643902B2 (en) 2020-08-12 2026-06-02 Sun Pharmaceutical Industries, Inc. Process for preparing enantiomerically enriched substituted pyrrolo[2,3-d]pyrimidines
US20220213105A1 (en) 2020-08-12 2022-07-07 Concert Pharmaceuticals, Inc. Process for preparing enantiomerically enriched jak inhibitors
CN116916927A (zh) * 2020-10-28 2023-10-20 太阳医药工业公司 用于用氘化jak抑制剂治疗脱发症的方案
US20230390292A1 (en) * 2020-10-28 2023-12-07 Sun Pharmaceutical Industries, Inc. Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
CN112402615A (zh) * 2020-11-11 2021-02-26 长沙晶易医药科技有限公司 一种用于治疗斑秃的复方外用制剂及其制备方法
WO2023018904A1 (en) 2021-08-11 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
AU2022328282A1 (en) 2021-08-12 2024-02-22 Sun Pharmaceutical Industries, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
WO2023215520A1 (en) 2022-05-04 2023-11-09 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
US12247034B1 (en) 2024-04-19 2025-03-11 Sun Pharmaceutical Industries, Inc. Crystalline form of deuruxolitinib phosphate
WO2026020112A1 (en) * 2024-07-19 2026-01-22 Sun Pharmaceutical Industries, Inc. Oral formulations of deuruxolitinib
US20260027120A1 (en) * 2024-07-25 2026-01-29 Sun Pharmaceutical Industries, Inc. Methods of treatment of jak inhibition responsive conditions with deuterated jak inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
CZ20033211A3 (cs) 2001-05-03 2004-09-15 F. Hoffmann-La Roche Ag Farmaceutická léková forma amorfního nelfinavir mesylátu
WO2006039237A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
WO2010083283A2 (en) 2009-01-15 2010-07-22 Incyte Corporation Processes for preparing jak inhibitors and related intermediate compounds
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
PT2635299T (pt) * 2010-11-02 2019-10-14 Univ Columbia Métodos de tratamento de distúrbios de perda de cabelo
DK2830662T3 (da) 2012-03-29 2019-01-02 Univ Columbia Fremgangsmåder til behandlng af hårtabsforstyrrelser
EP3450434B1 (en) 2012-06-15 2021-02-24 CoNCERT Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
CA2879400A1 (en) * 2012-07-30 2014-02-06 Concert Pharmaceuticals, Inc. Deuterated ibrutinib
KR102242077B1 (ko) * 2012-11-15 2021-04-20 인사이트 홀딩스 코포레이션 룩솔리티니브의 서방성 제형
JP6367545B2 (ja) * 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
CN104725380B (zh) * 2013-12-18 2019-06-28 康塞特医药品有限公司 卢索替尼的氘代衍生物
MX2016010213A (es) * 2014-02-07 2017-04-13 Auspex Pharmaceuticals Inc Formulaciones farmaceuticas novedosas.
US10561659B2 (en) 2016-05-04 2020-02-18 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors
WO2023018904A1 (en) * 2021-08-11 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders

Also Published As

Publication number Publication date
EP4424367A3 (en) 2024-11-13
JP2019516684A (ja) 2019-06-20
MX388054B (es) 2025-03-19
JP7586868B2 (ja) 2024-11-19
EP3452039A4 (en) 2019-12-25
AU2017261286B2 (en) 2023-03-23
SI3452039T1 (sl) 2024-12-31
JP2025026895A (ja) 2025-02-26
MX2023002325A (es) 2023-03-22
EP4424367A2 (en) 2024-09-04
AU2017261286A1 (en) 2018-11-22
AU2023201112B2 (en) 2025-05-08
JP7145080B2 (ja) 2022-09-30
US20200222408A1 (en) 2020-07-16
CN122440641A (zh) 2026-07-24
US10561659B2 (en) 2020-02-18
US20240423986A1 (en) 2024-12-26
ES2988629T3 (es) 2024-11-21
HUE068643T2 (hu) 2025-01-28
KR102810262B1 (ko) 2025-05-19
PL3452039T3 (pl) 2024-11-18
EP3452039B1 (en) 2024-07-03
CA3022519A1 (en) 2017-11-09
LT3452039T (lt) 2024-10-25
BR112018072339A2 (pt) 2019-02-19
MX2023002323A (es) 2023-03-22
FI3452039T3 (fi) 2024-10-02
JP2022171838A (ja) 2022-11-11
DK3452039T3 (da) 2024-10-07
MX2021014175A (es) 2022-01-04
AU2025213576A1 (en) 2025-08-21
MX2018013347A (es) 2019-09-02
MX2023002321A (es) 2023-03-22
HRP20241345T1 (hr) 2024-12-20
AU2023201112A1 (en) 2023-03-30
PT3452039T (pt) 2024-10-07
KR20250070139A (ko) 2025-05-20
KR20230086814A (ko) 2023-06-15
MX2023002324A (es) 2023-03-22
CN109069493A (zh) 2018-12-21
WO2017192905A1 (en) 2017-11-09
CN121868312A (zh) 2026-04-17
SMT202400389T1 (it) 2024-11-15
US20190160068A1 (en) 2019-05-30
US12076323B2 (en) 2024-09-03
EP3452039A1 (en) 2019-03-13
RS66006B1 (sr) 2024-10-31

Similar Documents

Publication Publication Date Title
JP7586868B2 (ja) 重水素化ｊａｋ阻害剤による脱毛障害の処置
US9776973B2 (en) Deuterated momelotinib
US20170189406A1 (en) Deuterated baricitinib
JP2024531188A (ja) 重水素化ｊａｋ阻害剤による脱毛障害の治療
JP2025515051A (ja) 重水素化ｊａｋ阻害剤による治療のための投与レジメン
WO2012129381A1 (en) Deuterated preladenant
HK40112813A (en) Treatment of hair loss disorders with deuterated jak inhibitors
EA052710B1 (ru) Лечение нарушений, характеризующихся выпадением волос, с помощью дейтерированных ингибиторов jak
HK40002100A (en) Treatment of hair loss disorders with deuterated jak inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

T16-X000 Administrative procedure resumed

St.27 status event code: U-3-3-T10-T16-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

J301 Trial decision

Free format text: TRIAL NUMBER: 2023101001201; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20230605

Effective date: 20240830

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 20240830

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2018 7034867

Appeal request date: 20230605

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2023101001201

J121 Written withdrawal of request for trial
PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202

PJ1201 Withdrawal of trial

St.27 status event code: A-3-3-V10-V13-apl-PJ1201

WITB Written withdrawal of application